PHASE I DOSE ESCALATING STUDY OF RHIL 12 WITH ADVANCED MALIGNANCIES

RHIL 12 治疗晚期恶性肿瘤的 I 期剂量逐步升级研究

• 批准号: 3743204
• 负责人: MICHAEL S GORDON
• 金额: --
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3743204
• 关键词: antineoplastics; biological response modifiers; clinical trials; cytokine; drug screening /evaluation; human subject; human therapy evaluation; neoplasm /cancer; neoplasm /cancer immunotherapy; recombinant proteins

We will be conducting a phase I trial with the new biological response modifier rhIL-12. rhIL-12 has been shown to possess a wide variety of immunologic effects which include the enhancement of anti-tumor activity of various effector cells.

我们将针对新的生物反应进行一期试验 修饰剂 rhIL-12。 rhIL-12 已被证明具有多种 免疫作用，包括增强抗肿瘤活性 各种效应细胞。